朱向阳

华奥泰生物医药有限公司总经理

华奥泰生物制药公司，华博生物医药技术有限公司（华海制药）总经理朱向阳博士是拥有16年生物制药研发和工艺开发方面的专家。在单抗筛选和鉴定，双靶点抗体的工程改造，细胞株的建立，工艺开发, 技术转移, 中试厂房的设计和建设等领域拥有丰富经验。目前，朱向阳负责华海制药的全球生物制药研发。 加入华海制药之前，曾长期在勃林格殷格翰（BI）的不同领域和地点工作，领导和参与了30多个单抗或双靶点抗体项目的研究，其中包括目前临床二期和三期的项目。朱向阳是单抗rasankizumab的发明人和项目负责人 朱向阳在BI期间，还参与了多个生物产品的工艺开发，中试厂房的设计和建设。朱向阳获得伊利诺伊大学免疫学博士学位。朱向阳是“国家千人”特聘专家

Raphael Graeter

勃林格殷格翰工艺验证及质量负责人

Raphael Graeter is the Head of Process Validation at Boehringer Ingelheim Biopharmaceuticals (China) Ltd.in Shanghai, China. His responsibilities include establishing validation strategies, management, and guiding Boehringer Ingelheim’s direction for validation activities. Before moving to China, he was employed at Boehringer Ingelheim’s biggest mammalian production site in Germany, where he worked on several biopharmaceutical manufacturing processes as the Validation Manager. Initially, Raphael developed his validation, aseptic- and process operational skills at one of the word leading companies in their field, Vetter Pharma, being in charge of managing the production. He shared his knowledge with ambitious students at IHK Ulm, where he besides his professional career, worked as a free-lance lecturer for biotechnology. As graduate from University of Applied Sciences, Raphael holds a degree in pharmaceutical biotechnology. When not hard at work, doing process validation, he enjoys home brewing and traveling the East Asia region with visiting Chinas beautiful country sites.

冯辉

君实生物首席运营官